The webinar either no longer exists or an error has occured.
Date: December 12, 2017
Time: 12:00 pm  to  1:00 pm CST

Join specialty pharmacist Stevan Lalich of CVS Health as he breaks down the differences between biosimilar, biologic, generic, and brand name drugs – and why it’s important! In this comprehensive webinar, learn about the medicines in your cabinet and the process they endure before reaching you. This is a timely and unique webinar not to be missed.

Your registration is important – even if you can’t attend live we’ll share the slides, video & audio of the presentation directly to you!

Presented By:

Stevan Lalich, Pharm.D.

Stevan Lalich has served in several clinical roles during his current 5-year tenure at CVS Health. In his current role, he focuses on developing and executing payer strategies specifically for the oncology therapy class.

Prior to this current position Stevan served as the Oncology Clinical Therapy Manager on the Specialty Manufacturer Services Team, where his scope of responsibility focused on clinical oversight of the oncology drug therapy portfolio for the specialty business unit.

This included serving as primary clinical point of contact for over 40 specialty pharmaceutical manufacturers overseeing all business opportunity partnerships and clinical needs as it pertains to the specialty pharmacy business including facilitating the preparation and launch of new-to-market oncology specialty pharmacy products and associated clinical adherence programs at CVS to ensure readiness of all internal stakeholders upon drug’s FDA approval and commercialization into the marketplace.

He also served as the oncology subject matter expert for the CVS Specialty Trade team for consultant RFP responses and manufacturer capabilities presentations in efforts to secure access to oncology pipeline assets. Stevan regularly provides oncology-related clinical therapy training across the organization to various audiences as needed including specialty pharmacy operations personnel and oncology prescriber team members.

Stevan obtained his Pharm.D. degree from the University of Illinois.

Other Resources:

FDA Approves First Biosimilar to Treat Cancer

Blog-Biosimilar Drugs

Biosimilars Mini-Magazine

Sponsored By:

Register Now!